ClinicalTrials.gg
CompletedNCT05182034Updated Feb 5, 2025

Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

A Phase 2 interventional study of SMUP-IA-01(low dose) and SMUP-IA-01(mid dose) in Knee Osteoarthritis, sponsored by Medipost Co Ltd.. Completed at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Medipost Co Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Enrollment
50th of 85
94 · median 124
Started
2022
with 6 others
Phase 2
14 of 96
1 open now
Registered
67th of 96
by date
Lead sponsor
4 of 96
Medipost Co Ltd.

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 50th largest by enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2022, is one of 14 in phase 2, and was the 67th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.

Read the detailed description

Patients who meet the inclusion/exclusion criteria will be randomly assigned at visit 2 to either of study group 1(low-dose), study group 2 (mid-dose) or active control group at 1:1:1 ratio. Patients will be administered with investigational product. Investigational product will be administered into the to-be-treated (index) knee one time within 7 days after randomization.

All patients enrolled will be followed up a total of 6 times (1, 4, 8, 12, 24, and 52 weeks) for up to post-dose 12 months. The patients should visit the study facility according to the visit schedule, and will undergo safety evaluation (vital sign, laboratory test, etc.) and efficacy evaluation [Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS), International Knee Documentation Committee (IKDC) subjective knee evaluation].

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • human umbilical cord blood derived mesenchymal stem cells
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are ≥ 19 years of age on the date on which the consent form was signed
  2. Patients diagnosed with knee osteoarthritis in at least one knee according to the clinical and radiological definition criteria of American College of Rheumatology (ACR) guidline at screening visit
  3. Patients with knee OA corresponding to K\&L Grade 2 or 3 on radiographic examination at screening visit
  4. Patients with less than 35 of at screening visit
  5. Patients who voluntarily decide to participate and sign the consent form
  6. Patients who have persistent symptoms despite having undergone a reasonable trial of standard therapy (i.e., for a minimum of 3 months)

Exclusion criteria

Exclusion Criteria:

  1. Patients with any of the following diseases.

    • infectious arthritis, or inflammatory joint diseases, gout, recurrent pseudogout, Paget's disease, intra-articular displaced fracture, ochronosis, acromegaly, haemochromatosis, Wilson's disease, genetic disease (hyperkinesia etc.), genetic collagen disorder, etc.
  2. Patients who have ever undergone surgery or radiotherapy in the knee joint area within the 12 weeks prior to the screening visit date, or who have not been recovered from its side effect yet.
  3. Patients with SIF (Subchondral insufficiency fracture) corresponding to type II of the RPOA (rapidly progressive osteoarthritis).
  4. Patients whose physical examination results show severe degree of ligament instability.
  5. Patients who have ever been given any intraarticular drug injection (i.e., hyaluronic acid injection, etc.) in to-be-treated (index) knee within the 6 months, prior to the screening visit date.
  6. Patients who have ever been given via intraarticular injection in to-be-treated (index) knee within the 12 weeks prior to the screening visit date.
  7. Patients who have ever taken medications or given therapy below within the past 2 weeks on the basis of screening visit date. However, if patients have 14 days of , the patient is allowed to participate.

    • drugs containing the ingredient of glucosamine, chondroitin sulfate, or diacerein
    • drugs containing herbal ingredient or herbal drugs for knee OA pain relief
    • anti-inflammatory analgesics or NSAIDs (prescription/non-prescription drugs). (However, patients who take acetaminophen and have 3 days of wash-out period are allowed to participate.)
    • oral steroids
    • hospital physiotherpy or oriental medicine treatment (buhang, acupunture, moxibustion etc.)
  8. Patients who have skin disease on injection site or who are judged inappropriate for intra-articular injection on to-be-treated knee.
  9. Patients who are judged unsuitable for MRI scanning (3.0 Tesla or higher) due to an insertion of metal material (i.e., heart pacemaker, cerebral aneurysm clip, etc.) or obstructive phobia. However, patients who have an insertion of metal material that is not affected by the magnetic field is allowed to participate
  10. Patients with past or present illness as follows;

    • heart diseases (i.e., myocardial infarction, coronary artery bypass surgery, arrhythmia and other serious heart diseases, etc.)
    • uncontrolled hypertension (not controlled down to 140/90 mmHg or below even after treatment with 3 or more antihypertensive drugs)
    • kidney disease (i.e., chronic kidney failure, glomerulonephritis, etc.)
    • liver disease (i.e., acute or chronic liver disease such as cirrhosis, fatty liver, etc.)
    • endocrine diseases (i.e., thyroiditis, diabetes insipidus, Cushing's disease, etc.)
    • other serious systemic diseases
  11. Patient with ongoing autoimmune disorder that requires treatment with an medication
  12. Patients with infection that requires administration of parenteral antibiotics
  13. Patients with a history of mental illness or epilepsy
  14. Patients who have been diagnosed with cancer within the 5 years prior to the screening visit date
  15. Patients who have been given immunosuppressive drugs such as cyclosporin A or azathioprine within the 6 weeks prior to the screening visit
  16. Patients with a history of allergic reactions to hyaluronic acid injections, cryoprotectant (dimethyl sulfoxide, DMSO), or gentamicin.
  17. Patients who are pregnant or lactating, or patients who have a plan to become pregnant during the study period
  18. Male or female patients who do not agree to avoid pregnancy or the use of appropriate methods during the study period. But women who have given infertility surgery or who have passed menopause one year or more are allowed to participate without the consent for contraception.
  19. Patients who have been given any other cell therapy products or who plan to do so during the study period.
  20. Patients who have been given any other products including device within the 3 months prior to the screening visit date.
  21. Patients who are judged by the investigator as inappropriate for enrollment into the study, for any reasons other than the reasons specified above.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Study Group 1: SMUP-IA-01 (low dose)

    Investigational Product - 4.0×10\^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(low dose)

  • Experimental
    Study Group 2:SMUP-IA-01 (mid dose)

    Investigational Product - 1.0×10\^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(mid dose)

  • Active comparator
    Active Control Group

    Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)

    Drug: Active Control Group Sodium chloride

Interventions

  • BiologicalSMUP-IA-01(low dose)

    A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

    Also known as: SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell)

  • BiologicalSMUP-IA-01(mid dose)

    A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

    Also known as: SMUP allogenic cord blood-derived mesenchymal stem cell (SMUP-Cell)

  • A single knee administration of Sodium chloride

    Also known as: Sodium chloride

06

What researchers measure

Primary outcomes

  1. Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline

    Total score is between 0 point (no symptoms) \~ 96 points (higher score representing worse symptoms).

    Time frame: Baseline, 52 week

Secondary outcomes

  1. Change amount of WOMAC total score at post-dose 24 weeks from the baseline

    Total score is between 0 point (no symptoms) \~ 96 points (higher score representing worse symptoms).

    Time frame: Baseline, 24 week

  2. Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline

    The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68)

    Time frame: Baseline, 24 week, 52 week

  3. Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline

    The score ranges from "0" or no pain to "100" very severe pain

    Time frame: Baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52 week

  4. Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline

    IKDC subjective knee evaluation consists of three categories: symptoms, sports activities, and functions. For each category, there are 7 questions for symptoms, 2 questions for sports activities, and 2 questions for functions, a total of 11 questions for evaluation. The scores for each category are summed up and divided into 87, which is the maximum score possible, and then is evaluated by converting it into a scale of 100 points. Higher score indicates better function and less symptoms for the knee.

    Time frame: Baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52 week

  5. Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline

    Total score is between 0 point (no symptoms) \~ 96 points (higher score representing worse symptoms).

    Time frame: Baseline, 52 week

  6. Change in T2 mapping at post-dose 52 weeks from the baseline

    Changes on the knee structure through qualitative and quantitative evaluation of the collagen matrix of knee cartilage.

    Time frame: Baseline, 52 week

  7. Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline

    K \& L grade (0 to 4 Grade): which means that the higher the grade, the greater the joint damage and the stenosis of the joint. Joint space width(mm): Evaluation of disease progression in target knee as ascertained by change from baseline joint space width (JSW) determined using radiography. Mechanical axis(Angle): A line connecting the femoral head center point and the ankle joint center point. Anatomical axis(Angle): The middiaphyseal line of the femur and tibia

    Time frame: Baseline, 52 week

  8. Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.

    serum C-terminal cross-linking telopetides of collagen type I(CTX-I), serum hyaluronan, serum matrix metalloproteinase-3 (MMP-3), urine C-terminal cross-linking telopetides of collagen type II (CTX -II), urine C-terminal cross-linking telopetides of collagen type I(CTX-I). Serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II are reported in pg/ml.

    Time frame: baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52week

  9. Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks

    Subjects will receive Patient Diary, and use of the rescue drug should be recorded on the Patient Diary.

    Time frame: 1 week, 4 week, 8 week, 12 week, 24 week, 52week

07

Study locations

5 sites
  • Seoul Nation University Bundang Hospital
    Gyeonggi-do, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospita
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Oct 2023, 19 months.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 19 months is close to that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2021
First posted
Jan 10, 2022
StartActual
Feb 24, 2022
Primary completionActual
Oct 17, 2023
CompletionActual
Oct 17, 2023
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05182034
Lead sponsor
Medipost Co Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
Feb 24, 2022
Primary completion
Oct 17, 2023
Completion
Oct 17, 2023
Last update
Feb 5, 2025

Study contacts

Myungchul Lee, MD, PhD
principal investigator · Seoul National University Hospital
Chonghyuk Choi, MD, PhD
principal investigator · Severance Hospital
Chongbum Chang, MD, PhD
principal investigator · Seoul Nation University Bundang Hospital
Seungbum Han, MD, PhD
principal investigator · Korea University Anam Hospital
Sunghwan Kim, MD, PhD
principal investigator · Gangnam Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion